OverviewSuggest Edit

Amarillo Biosciences (ABI) is a healthcare company that specializes in the discovery and development of novel biopharmaceuticals, medical treatments, and specialty consumer products. It is engaged in the clinical trials of low-dose oral interferon as a therapeutic treatment for thrombocytopenia, Sjögren's syndrome, hepatitis C virus (HCV), and influenza indications. In addition, the company develops a treatment to address metabolism related diseases such as T1 and T2 diabetes using a pulsatile insulin infusion therapy that mimics the normal pancreas’ functions.
TypePublic
Founded1984
HQAmarillo, TX, US
Websiteamarbio.com

Latest Updates

Employees (est.) (Dec 2019)2(-50%)
Revenue (FY, 2020)$16.6 K(+42%)
Share Price (Jul 2021)$0.9
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Amarillo Biosciences

Stephen T. Chen

Stephen T. Chen

Chairman & CEO
Bernard H. Cohen

Bernard H. Cohen

Vice President
John Junyong Lee

John Junyong Lee

Corporate Legal Counsel
Yasushi Chikagami

Yasushi Chikagami

Board Member
Daniel Fisher

Daniel Fisher

Board Member
Nicholas Moren

Nicholas Moren

Board Member
Show more

Amarillo Biosciences Office Locations

Amarillo Biosciences has offices in Amarillo and Taipei
Amarillo, TX, US (HQ)
4134 Business Park Dr
Taipei, TW
7/F, No. 58, Sec 1, Minsheng East Road Zhongshan District
Show all (2)

Amarillo Biosciences Financials and Metrics

Amarillo Biosciences Revenue

Embed Graph
View revenue for all periods
Amarillo Biosciences's revenue was reported to be $16.56 k in FY, 2020
USD

Revenue (Q1, 2021)

2.1k

Gross profit (Q1, 2021)

872.0

Gross profit margin (Q1, 2021), %

41.1%

Net income (Q1, 2021)

(534.0k)

EBIT (Q1, 2021)

(522.1k)

Market capitalization (22-Jul-2021)

25.2m

Closing stock price (22-Jul-2021)

0.9

Cash (31-Mar-2021)

9.4k
Amarillo Biosciences's current market capitalization is $25.2 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

250.9k77.7k11.7k16.6k

Revenue growth, %

(69%)(85%)

Cost of goods sold

60.3k64.9k8.8k11.3k

Gross profit

190.6k12.8k3.0k5.3k
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

56.6k250.014.9k4.1k606.04.8k15.2k484.0192.02.1k

Cost of goods sold

43.3k707.016.8k2.7k563.03.4k10.8k292.0123.01.2k

Gross profit

13.3k(457.0)(1.9k)1.4k43.01.4k4.4k192.069.0872.0

Gross profit Margin, %

23%(183%)(13%)33%7%30%29%40%36%41%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

2.0m1.3m409.0k22.2k

Accounts Receivable

Prepaid Expenses

23.6k26.6k32.1k51.1k

Inventories

22.7k4.1k3.0k
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

1.7m1.4m1.1m1.0m723.4k482.8k289.6k172.8k83.8k9.4k

Accounts Receivable

2.2k6.7k4.2k12.6k751.0751.0

Prepaid Expenses

10.3k64.5k46.2k16.0k64.6k58.5k25.7k14.6k70.0k32.9k

Inventories

9.0k9.9k6.4k4.1k3.7k3.5k
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(617.4k)(1.3m)(1.6m)(1.5m)

Depreciation and Amortization

40.0k56.2k22.2k14.7k

Inventories

(8.0k)22.7k(4.1k)1.1k

Accounts Payable

(9.5k)54.8k261.7k419.6k
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(534.0k)

Cash From Operating Activities

(76.5k)(389.4k)(697.3k)(216.2k)(539.1k)(779.3k)(119.5k)(245.0k)(408.4k)(119.5k)

Capital Expenditures

(4.9k)(1.6k)(1.6k)

Cash From Investing Activities

(1.7k)(2.1k)55.6k(1.6k)(1.6k)(2.0k)(1.3k)(1.9k)
USDFY, 2017

Revenue/Employee

83.6k

Debt/Equity

1.9 x

Debt/Assets

0.4 x

Financial Leverage

4.9 x
Show all financial metrics

Amarillo Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Amarillo Biosciences Online and Social Media Presence

Embed Graph

Amarillo Biosciences News and Updates

Amarillo Biosciences, Inc. Enters into a Securities Purchase Agreement to Foster New Growth

Amarillo Biosciences, Inc. ("we," "ABI" or the "Company"), (OTC PINK:AMAR), a company engaged in low-dose non-injectable interferon research, announced today that it has entered into a Securities Purchase Agreement ("Agreement") with a strategic investor, Ainos, Inc., a Cayman Islands corporation ("…

Amarillo Biosciences to Initiate Low-Dose Interferon Clinical Trials to Treat COVID-19, Appoints Interferon Specialist Dr. Manfred Beilharz to Scientific Advisory Board

Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), the world leader in low-dose non-injectable interferon research, is pleased to announce the appointment of Dr. Manfred Beilharz, Associate Professor at The University of Western Australia and renown pioneer in interferon research, to the C…

Amarillo Biosciences to Reaffirm Low-Dose Interferon Research Leadership Position and Global Commitment to Support Related Therapeutics

Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), a diversified healthcare company, today announced that it is taking steps to reaffirm its position as the world leader in low-dose non-injectable interferon research. ABI will strengthen its commitment to bring its products to market by s…

Amarillo Biosciences to Explore Low-Dose Oral Interferon Therapeutics in China as a Line of Defense Against Coronavirus and Other Viral Indications

Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), a diversified healthcare company, today announced that its China licensing partner, Xiamen Weiyang Pharmaceutical Co., Ltd. (“Xiamen Weiyang”), has begun initiating the sharing of proprietary clinical research information with health offic…

Amarillo Biosciences and Xiamen Weiyang Pharmaceutical Sign Term Sheet Outlining China Licensing and Royalty Agreement

Amarillo Biosciences, Inc. (“ABI” or the “Company”), (OTCBB: AMAR), a diversified healthcare company, today announced that it has entered into a Term Sheet outlining a licensing and royalty agreement with Xiamen Weiyang Pharmaceutical Co., Ltd., a company organized under the laws of the People’s Rep…

Amarillo Biosciences First-Half 2018 Business Update

Amarillo Biosciences, Inc. (ABI), (OTCBB: AMAR), a diversified healthcare company, today provided an update on its first-half 2018 results and recent business activities

Amarillo Biosciences Frequently Asked Questions

  • When was Amarillo Biosciences founded?

    Amarillo Biosciences was founded in 1984.

  • Who are Amarillo Biosciences key executives?

    Amarillo Biosciences's key executives are Stephen T. Chen, Bernard H. Cohen and John Junyong Lee.

  • How many employees does Amarillo Biosciences have?

    Amarillo Biosciences has 2 employees.

  • What is Amarillo Biosciences revenue?

    Latest Amarillo Biosciences annual revenue is $16.6 k.

  • What is Amarillo Biosciences revenue per employee?

    Latest Amarillo Biosciences revenue per employee is $8.3 k.

  • Who are Amarillo Biosciences competitors?

    Competitors of Amarillo Biosciences include Zikani Therapeutics, Sentien Biotechnologies and Entera Bio.

  • Where is Amarillo Biosciences headquarters?

    Amarillo Biosciences headquarters is located at 4134 Business Park Dr, Amarillo.

  • Where are Amarillo Biosciences offices?

    Amarillo Biosciences has offices in Amarillo and Taipei.

  • How many offices does Amarillo Biosciences have?

    Amarillo Biosciences has 2 offices.